A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

Sickle Cell Disease Clinical Trial

Official title:

Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04055818
• Other study ID #: 2019-0631
• Secondary ID: P01HL146372R44HL
• Status: Recruiting
• Phase: Phase 1
• Start date: January 24, 2020
• Est. completion date: April 5, 2024

Study information

• Verified date: April 2023
• Source: EpiDestiny, Inc.
• Contact: Lani Krauz
• Phone: 312-413-0242
• Email: LIgnacio[@]UIC.EDU
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).

Description:

A randomized control trial comparing oral THU-decitabine to nicotinamide (1:1 randomization), and then comparing the effects of the combination of nicotinamide with THU-decitabine vs either treatment alone. Treatment with each agent alone is for 12 weeks followed by the combination for a further 12 weeks. Patients have the option to enter an extension phase of combination treatment for an additional 24 weeks (total of 48 weeks)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: April 5, 2024
• Est. primary completion date: March 8, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older.

• Written informed consent provided by the subject before study entry.

• Confirmed sickle cell disease (SCD) as determined by hemoglobin electrophoresis or liquid chromatography.

• Subject is in his/her steady state and not having any acute complication due to SCD (i.e., hospitalization, acute pain, or acute chest syndrome in the past 14 days).

• Weight at least 40kg

• Regular compliance with comprehensive care and previous therapy.

• Symptomatic SCD is defined as having one of following, despite at least 6 months of hydroxyurea therapy, or refuse to take hydroxyurea for personal reasons: fetal hemoglobin <0.5 g/dL, or 3 or more pain episodes per year requiring parenteral narcotics, or 1 or more acute chest syndrome episodes, or Hemoglobin <9 g/dL and absolute reticulocyte count <250,000/mm3.

Exclusion Criteria:

• Inability to give informed consent.

• Experienced severe sepsis or septic shock within the previous 12 weeks.

• Last HU dose was ingested within the previous 4 weeks.

• Currently pregnant or breast-feeding.

• Alanine Aminotransferase (ALT) = 3 times the upper limit of normal or albumin <2.0 mg/dL or direct (conjugated) bilirubin = 1.5 mg/dl.

• Serum creatinine >2.9 mg/dL and calculated creatinine clearance <30 mL/min.

• Platelet count >800 x 109/L.

• Absolute neutrophil count <1.5 x 109/L.

• Female of active childbearing potential who is unwilling to use at least one of the two following forms of birth control: (i) not having heterosexual sexual contact beginning at the screening visit and continuing until 4 weeks after the last dose of decitabine OR (ii) intrauterine device (IUD).

• Sexually active male who is unwilling to use a condom when engaging in any sexual contact with a female with child-bearing potential, beginning at the screening visit and continuing until 4 weeks after taking the last dose of THU and decitabine. This requirement applies also to males who have had a successful vasectomy.

• Altered mental status or recurrent seizures requiring anti-seizure medications.

• Moribund or any concurrent disease (e.g., hepatic, renal, cardiac, metabolic) of such severity that death within 24 weeks is likely.

• Concurrent diagnosis of malignancy including known Myelodysplastic syndrome, leukemia, or an abnormal karyotype.

• New York Heart Association (NYHA) class III/IV status.

• Eastern Co-operative Oncology Group (ECOG) performance status =3.

• Participant is on chronic transfusion therapy

• Known history of illicit drug or alcohol abuse within the past 12 months.

• Other experimental or investigational drug therapy in the past 28 days.

• Taking l-glutamine within the last 28 days

• Being positive for HIV infection

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• Nicotinamide
Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination

Locations

Country	Name	City	State
United States	University of Illinois at Chicago College of Medicine	Chicago	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
EpiDestiny, Inc.	National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Hemoglobin	Measure hemoglobin function	12 weeks